CD274 and non-small cell lung carcinoma: Anti‐PD‐1/PD‐L1 antibodies, such as nivolumab, pembrolizumab, and atezolizumab have demonstrated promising and amazing efficacy against various tumors in several clinical trials, especially those involving NSCLC 7, 8, 9, 10.